XLO Xilio Therapeutics, Inc.: institutional ownership and insider trading
27 funds reported holding $26.4M of Xilio Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $7.59M, with 11 new positions and 7 funds selling out; over the last 12 months insiders bought $44.0K and sold $5.67K on the open market; over its last four quarters it reported revenue of $64.1M and net income of −$21.8M.
XLO revenue and earnings
- Quarter ended Jun 30, 2026: revenue $18.7M, net income −$6.37M, EPS -0.33
- Quarter ended Mar 31, 2026: revenue $12.6M, net income −$9.53M, EPS -0.58
- Quarter ended Dec 31, 2025: revenue $13.7M, net income $10.4M, EPS 0.71
- Quarter ended Sep 30, 2025: revenue $19.1M, net income −$16.3M, EPS -0.11
Famous investors holding XLO
- Renaissance Technologies (Renaissance Technologies): $615K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $249K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $139K, 0.0% of the portfolio
Largest institutional holders of XLO
- Bain Capital Life Sciences Investors, LLC — $6.36M
- ORBIMED ADVISORS LLC — $5.67M
- Frazier Life Sciences Management, L.P. — $4.05M
- Stonepine Capital Management, LLC — $2.17M
- VANGUARD CAPITAL MANAGEMENT LLC — $1.71M
- Sio Capital Management, LLC — $1.46M
- ADAGE CAPITAL PARTNERS GP, L.L.C. — $1.07M
- Merck & Co., Inc. (MRK) — $1.02M
- RENAISSANCE TECHNOLOGIES LLC — $615K
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $546K
Recent XLO insider trades
- Mar 26, 2026: Shannon James Samuel bought 5,000 shares ($44.0K)
- Jan 2, 2026: Brennan Kevin M. sold 1,826 shares ($1.17K)
- Jan 2, 2026: Frankenfield Christopher James sold 7,030 shares ($4.50K)
- Jun 17, 2025: Shannon James Samuel bought 70,000 shares ($48.3K)
5%+ owners
- BCLS II Equity Opportunities, LP: 10.0% (Schedule 13G/A, filed May 15, 2026)
- StemPoint Capital LP: 9.5% (Schedule 13G/A, filed Aug 14, 2026)